Article
Top 5 Most-Read SAP Content of 2022
Author(s):
The most-read articles related to our Strategic Alliance Partnership (SAP) program focused on behavioral health, oncology care, and partner news.
The top 5 most-read articles and interviews articles related to our Strategic Alliance Partnership (SAP) program on AJMC.com this year included information on cost-effective oncology with genomic profiling, interviews with leaders in cancer care and behavioral health, and covering news about pharmacy benefit managers (PBMs).
Here are the 5 most-viewed SAP articles of 2022.
5. How Employers Can Achieve High-Value, Cost-Effective Oncology Care Through Genomic Profiling
A Community Oncology Alliance webinar that hosted experts to discuss the benefits of genomic profiling in oncology and the experts’ recommendations for employers and benefit consultants that are considering biomarker testing, according to this article published in February. Biomarker testing had been found to promote the use of targeted therapies that led to improvements in the survival of patients with diseases such as lung cancer.
4. Evaluating Value-Based Contracting in Behavioral Health: A Q&A With Vanessa Bobb, MD, PhD, FAPA
An interview with Vanessa Bobb, MD, PhD, FAPA, the vice president of Behavioral Health & Medical Integration at CDPHP, focused on how value-based programs can be used in mental health and substance abuse care. Bobb said that she would like behavioral health providers to be able to better engage with and support value-based programs. She also said that the health care industry should be considerate of providers that may not be able to participate in risk-based programs.
3. Dosing Study of Modakafusp Alfa Shows Promise in Solid Tumors; Tests Planned With Checkpoint Inhibitors
This article published in the July issue of Evidence-Based Oncology™ focused on results of the phase 1b/2 dose escalation study of modakafusp alfa, which were presented at the 2022 Annual Meeting of the American Society of Clinical Oncology (ASCO) by an investigator from Sarah Cannon Research Institute and Tennessee Oncology. Modakafusp alfa, a first-in-class immune-targeting attenuated cytokine, was found to have a manageable safety profile in the dose range of 0.1 to 1.5 mg/kg in patients with solid tumors. However, adverse events from treatment were reported in 81% of patients. Future studies would test modakafusp alfa with a checkpoint inhibitor in selected tumor types.
2. ASCO Spotlight With David R. Penberthy, MD, MBA: Knowledge Gained at ASCO Can Transform Cancer Care
In an interview published in the July issue of Evidence-Based Oncology™, David R. Penberthy, MD, MBA, president of the Association of Community Cancer Centers, discussed ways that the information presented at the ASCO meeting can change cancer care nationally and globally. Penberthy explained that digital tools can help achieve equity in clinical trial administration by giving doctors and other experts across the country the ability to speak to each other and come up with ways that work from one state to another.
1. NPC Weighs in on PBM Inquiry; Radiologist Receives Award; OneOncology Creates Disease Groups
An article published in the August issue of Evidence-Based Oncology™ covers an inquiry into the PBM industry by the Federal Trade Commission (FTC) and the response from the National Pharmaceutical Council. The inquiry by the FTC will investigate how merging health plans with specialty pharmacy providers affected drug prices and prescriptions from doctors for treatments that are best for patients. The move came after PBMs had started making or breaking a drug’s ability to secure a position in the market due to price and fee negotiations with drug manufacturers.
